A Remarkable CAR-T Immunotherapy Journey from Pakistan to Shanghai

In a remarkable journey highlighting the potential of advanced medical therapies, a 36-year-old Pakistani patient named Muhammad has demonstrated significant improvement after receiving groundbreaking CAR-T immunotherapy at the Jiahui International Cancer Center, located in Shanghai.

Muhammad, an employee at a local hospital in Quetta, Pakistan, had been battling diffuse large B-cell lymphoma (DLBCL), an aggressive form of blood cancer. After enduring several rounds of chemotherapy and a failed bone marrow transplant, his condition deteriorated to Stage IVB by early 2026. This stage included extensive metastasis to the lungs, pleura, and bones, along with severe, persistent pain. Despite numerous treatments, local physicians confirmed that further conventional options were no longer effective, prompting the need for advanced treatment abroad. The Pakistani national medical board approved his application for international therapy following a comprehensive evaluation.

With multiple medical institutions considered, Muhammad ultimately chose the Jiahui International Cancer Center due to its efficient consultation services and the dedicated support offered to international patients.

Dr. Hao Siguo, the chief hematology consultant at Jiahui, designed a personalized CAR-T therapy regimen for Muhammad, taking into account the complexity of his case and the considerable tumor burden he faced. This involved a strategic bridging therapy that combined chemotherapy and localized radiotherapy aimed at reducing tumor size prior to the CAR-T cell infusion. This innovative approach not only lowered associated risks but also enhanced the overall effectiveness of the treatment.

Once his vital organ function stabilized, a multidisciplinary team at Jiahui moved forward with the tailored therapy. Following lymphocyte collection — the first step in the CAR-T process — and preparatory therapies intended to optimize his health for safe cell infusion, Muhammad received his personalized CAR-T cell infusion on April 23, 2026. Notably, during the observation period post-infusion, he only experienced mild cytokine release syndrome and did not suffer from severe neurotoxicity.

In a significant turnaround, Muhammad showed rapid clinical improvements, with severe cancer-related pain alleviated and a dramatic decrease in his reliance on opioid medications. Tests conducted before his discharge indicated a reduction in tumor lesions and normalization of critical laboratory indicators, signaling a positive response to the CAR-T treatment.

Throughout his medical journey, the Jiahui team's commitment to patient care was evident. They provided essential support, including professional translation services and halal meal options, catering to Muhammad's cultural and religious preferences.

Reflecting positively on his experience in China, Muhammad expressed gratitude for the cooperation he encountered, stating, "Chinese people are very cooperative. The doctors, nurses, and staff were incredibly supportive." He was discharged on May 7, 2026, and plans to continue his follow-up imaging and monitoring in Pakistan.

This case serves not only as a testament to the efficacy of CAR-T therapy for complex lymphoma cases but also highlights Jiahui International Cancer Center's commitment to delivering high-quality, patient-centric medical services that transcend borders. As the medical community continues to push the boundaries of cancer treatment, stories like Muhammad's inspire hope and underscore the importance of innovative healthcare solutions for patients around the globe.